[144] Alignment Healthcare, Inc. SEC Filing

Rhea-AI Filing Summary

Alignment Healthcare, Inc. (ALHC) filing a Form 144 reports a proposed sale of 107,223 common shares through Morgan Stanley Smith Barney LLC on 09/10/2025 for an aggregate market value of $1,767,035.04, with the securities to be sold on NASDAQ. The shares were acquired as restricted stock units on 09/07/2025 and payment is recorded as N/A. The filing also discloses prior sales by Dawn Maroney: 108,439 shares on 09/08/2025 (gross proceeds $1,779,483.99) and three earlier 10b5-1 plan sales of 30,000 shares each on 08/13/2025, 07/14/2025, and 06/16/2025 with stated gross proceeds. The filer attests there is no undisclosed material adverse information.

Positive

• Form 144 filed and details disclosed, demonstrating regulatory compliance and transparency
• Use of 10b5-1 plans for several prior sales, indicating preplanned trading rather than ad hoc insider timing

Negative

• Insider sales totaling significant shares in recent months (e.g., 108,439 on 09/08/2025), which some investors may view negatively
• Proposed sale of 107,223 shares shortly after RSU vesting (acquired 09/07/2025), indicating immediate disposition of newly acquired shares

Insights

Securities Analyst

TL;DR Insider sale of newly vested RSUs and several 10b5-1 plan sales; modest in scale relative to total shares outstanding.

The filing documents a proposed broker-mediated sale of 107,223 common shares valued at roughly $1.77 million and notes recent disposals by Dawn Maroney totaling approximately 198,878 shares across the listed dates. Given the issuer's stated outstanding share count of 198,031,417, the proposed sale represents a de minimis fraction of total equity, suggesting limited immediate dilution or market impact. The presence of 10b5-1 plan sales indicates preplanned dispositions rather than opportunistic trading. Materiality appears low, but investors may monitor for continued insider selling patterns.

Corporate Governance Expert

TL;DR Filing shows compliance with Rule 144 and disclosure of 10b5-1 plan activity; no explicit governance red flags disclosed.

The Form 144 includes required seller representations and indicates the securities were acquired as restricted stock units and are being sold under broker arrangements. The attestation that no undisclosed material adverse information exists and the citation of 10b5-1 sales support procedural compliance. There is no indication in this filing of departures, related-party transactions, or regulatory issues. From a governance perspective, this is a routine insider liquidity event with properly documented notices.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	107223	1767035.04	198031417	09/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/07/2025	Restricted Stock Units	Issuer			107223	09/07/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
DAWN MARONEY 1100 W. Town and Country Road Suite 1600 Orange CA 92868	Common	09/08/2025	108439	1779483.99
10b5-1 Sales for DAWN MARONEY 1100 W. Town and Country Road Suite 1600 Orange CA 92868	Common	08/13/2025	30000	447108.50
10b5-1 Sales for DAWN MARONEY 1100 W. Town and Country Road Suite 1600 Orange CA 92868	Common	07/14/2025	30000	403347.50
10b5-1 Sales for DAWN MARONEY 1100 W. Town and Country Road Suite 1600 Orange CA 92868	Common	06/16/2025	30000	434280.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ALHC Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 107,223 common shares via Morgan Stanley Smith Barney LLC on 09/10/2025 for an aggregate market value of $1,767,035.04 on NASDAQ.

When were the shares being sold by the filer acquired?

The shares were acquired as restricted stock units on 09/07/2025 and are listed as the securities to be sold.

Has the filer sold other ALHC shares recently?

Yes. The filing lists prior sales by Dawn Maroney including 108,439 shares on 09/08/2025 and three 10b5-1 sales of 30,000 shares each on 08/13/2025, 07/14/2025, and 06/16/2025 with stated gross proceeds.

What exchange will the shares be sold on?

The proposed sale is designated for NASDAQ.

Does the filing state whether the seller knows any undisclosed material information?

Yes. The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.